A good summary document on brilaroxazine from an investment research firm looking at Reviva.
https://s1.q4cdn.com/460208960/files/News/2021/Zacks_SCR_Research_01132021_RVPH_Vandermosten.pdf
You can see the important improvements compared to aripiprazole, eg target receptor binding and affinities, virtually non existent off-target binding, much improved side effect profile (see bar charts summarizing results from phase II trial and comparing to aripiprazole 15 mg).
There’s also a decent summary table comparing all the existing antipsychotics at target receptors.
They are starting phase III trials (for schizophrenia) this year and looks like if everything is successful will be FDA approved in 2025. They are also in earlier trials stages for other indications and looks like it has potential for quite a number of indications.